Molecular Cancer Therapeutics
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591).
20:P035-P035.
2021
-
Estrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia.
16:2618-2626.
2017
-
ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer.
10:1876-1885.
2011
-
Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts.
10:57-68.
2011
-
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.
8:64-74.
2009
-
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.
6:570-577.
2007
-
Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway.
5:3303-3311.
2006
-
Role of the transcription factor Ets-1 in cisplatin resistance.
3:823-832.
2004
-
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy..
1:545-552.
2002
-
Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years
2018
-
Abstract B29: A multicenter, open-label phase 1/2 study of oral CFG920, in combination with prednisone in adult patients with metastatic castration-resistant prostate cancer
2015
-
Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
2011
-
Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.
2011
-
Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).
2011
-
Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors
2009
-
Abstract B54: A phase 1 study to assess the safety, tolerability and pharmacokinetics of the ErbB-family inhibitor ARRY-334543 in patients with advanced solid tumors
2009
-
A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms
2007
-
AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium
2007
-
Fluororescence in situ hybridization (FISH) gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors (MSGT) treated with lapatinib
2007
-
Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers
2007
-
A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)